On Tuesday, Ginkgo Bioworks Holdings Inc (NYSE: DNA) was 1.91% up from the session before settling in for the closing price of $9.43. A 52-week range for DNA has been $5.26 – $75.20.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 104.75%. When this article was written, the company’s average yearly earnings per share was at 45.22%. With a float of $36.73 million, this company’s outstanding shares have now reached $41.37 million.
Considering the fact that the conglomerate employs 1218 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 63.73%, operating margin of -271.32%, and the pretax margin is -298.94%.
Ginkgo Bioworks Holdings Inc (DNA) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Ginkgo Bioworks Holdings Inc stocks. The insider ownership of Ginkgo Bioworks Holdings Inc is 32.58%, while institutional ownership is 47.96%. The most recent insider transaction that took place on Dec 17 ’24, was worth 923. Before that another transaction happened on Dec 16 ’24, when Company’s Officer proposed sale 99 for $9.35, making the entire transaction worth $926.
Ginkgo Bioworks Holdings Inc (DNA) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 45.22% per share during the next fiscal year.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) Trading Performance Indicators
You can see what Ginkgo Bioworks Holdings Inc (DNA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.79. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.53.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -12.90, a number that is poised to hit -1.50 in the next quarter and is forecasted to reach -5.81 in one year’s time.
Technical Analysis of Ginkgo Bioworks Holdings Inc (DNA)
Compared to the last year’s volume of 1.16 million, its volume of 1.34 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 13.66%. Additionally, its Average True Range was 0.90.
During the past 100 days, Ginkgo Bioworks Holdings Inc’s (DNA) raw stochastic average was set at 39.08%, which indicates a significant decrease from 40.90% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 116.34% in the past 14 days, which was higher than the 108.66% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.46, while its 200-day Moving Average is $19.01. Nevertheless, the first resistance level for the watch stands at $9.87 in the near term. At $10.13, the stock is likely to face the second major resistance level. The third major resistance level sits at $10.56. If the price goes on to break the first support level at $9.18, it is likely to go to the next support level at $8.75. Now, if the price goes above the second support level, the third support stands at $8.49.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) Key Stats
There are 57,479K outstanding shares of the company, which has a market capitalization of 552.38 million. As of now, sales total 251,460 K while income totals -892,870 K. Its latest quarter income was 89,050 K while its last quarter net income were -56,400 K.
